N-(2-chloro-5-(imidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide | 1313488-89-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(2-chloro-5-(imidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide
• 英文别名: N-(2-chloro-5-imidazo[1,2-b]pyridazin-6-ylpyridin-3-yl)-4-fluorobenzenesulfonamide
• CAS: 1313488-89-9
• 化学式: C₁₇H₁₁ClFN₅O₂S
• 分子量: 403.824
• InChiKey: WEIYGNUYMJRNTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.6
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-氯-3-氨基-5-溴吡啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 4.17h， 生成 N-(2-chloro-5-(imidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide
  参考文献：
  名称：

  Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability

  摘要：

  N-(6-(6-Chloro-5-(4-fluorophenylsulfonamido)pyridin-3-yl)benzo[d]thiazol-2-yl)acetamide (1) is a potent and efficacious inhibitor of PI3K alpha and mTOR in vitro and in vivo. However, in hepatocyte and in vivo metabolism studies, 1 was found to undergo deacetylation on the 2-amino substituent of the benzothiazole. As an approach to reduce or eliminate this metabolic deacetylation, a variety of 6,5-heterocyclic analogues were examined as an alternative to the benzothiazole ring. Imidazopyridazine 10 was found to have similar in vitro potency and in vivo efficacy relative to 1, while only minimal amounts of the corresponding deacetylated metabolite of 10 were observed in hepatocytes.

  DOI：

  10.1021/jm2004442

文献信息

• Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability
  作者：Markian M. Stec、Kristin L. Andrews、Shon K. Booker、Sean Caenepeel、Daniel J. Freeman、Jian Jiang、Hongyu Liao、John McCarter、Erin L. Mullady、Tisha San Miguel、Raju Subramanian、Nuria Tamayo、Ling Wang、Kevin Yang、Leeanne P. Zalameda、Nancy Zhang、Paul E. Hughes、Mark H. Norman

  DOI：10.1021/jm2004442

  日期：2011.7.28

  N-(6-(6-Chloro-5-(4-fluorophenylsulfonamido)pyridin-3-yl)benzo[d]thiazol-2-yl)acetamide (1) is a potent and efficacious inhibitor of PI3K alpha and mTOR in vitro and in vivo. However, in hepatocyte and in vivo metabolism studies, 1 was found to undergo deacetylation on the 2-amino substituent of the benzothiazole. As an approach to reduce or eliminate this metabolic deacetylation, a variety of 6,5-heterocyclic analogues were examined as an alternative to the benzothiazole ring. Imidazopyridazine 10 was found to have similar in vitro potency and in vivo efficacy relative to 1, while only minimal amounts of the corresponding deacetylated metabolite of 10 were observed in hepatocytes.